BBIO Form 144: Board-Related Insider Plans 1,542-Share Sale, $68 K Value

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) – Form 144 filing dated 26 June 2025 discloses a proposed Rule 144 sale by Hannah Valantine & Denis von Kaeppler, who are identified as the spouse and joint owner of a member of the Board of Directors. The filing covers 1,542 common shares to be sold through Morgan Stanley Smith Barney on or about 26 June 2025 on Nasdaq, carrying an aggregate market value of $67,863.42. With 189,880,720 shares outstanding, the planned sale represents roughly 0.0008 % of shares outstanding.

The form also reports insider activity over the prior three months: four separate sales dated 10 June 2025, each involving 4,292 shares at gross proceeds of roughly $171.6 k apiece, totalling 17,168 shares and ~$686 k. All securities were originally acquired on 28 Dec 2021 via an open-market purchase paid in cash.

No adverse non-public information is acknowledged, and the signatory affirms compliance with Rule 144 representations. From a capital-markets perspective, the volumes involved are immaterial relative to BridgeBio’s float and should not affect liquidity or ownership structure in a meaningful way. Nevertheless, continued insider selling—even in small lots—can be interpreted by some investors as a sentiment cue and merits monitoring alongside future insider transaction patterns.

Positive

• Sale size is immaterial at 0.0008 % of shares outstanding, limiting dilution and market impact.
• Proper Rule 144 compliance demonstrates transparent corporate governance procedures.

Negative

• Continued insider selling (total 17,168 shares over past three months) may be viewed as a bearish sentiment signal despite small absolute size.

Insights

Financial Analyst

TL;DR: Small insider sale (1,542 shares) is immaterial to BBIO float; signals worth noting but unlikely to move the stock.

The Rule 144 notice reflects a minimal disposition—0.0008 % of outstanding shares—by an insider’s spouse. Even aggregating the past-three-month sales (17,168 shares), the total remains under 0.01 % of the share count and below typical market-moving thresholds. Dollar proceeds (~$754 k combined) are also negligible versus BBIO’s ~$6 bn market cap. Therefore, the filing is not materially dilutive nor indicative of structural change. That said, sequential insider sales can influence perception, particularly in biotech where information asymmetry is high. Investors should watch for any acceleration in insider dispositions around clinical or regulatory catalysts.

Corporate Governance Expert

TL;DR: Routine compliance filing; governance impact minimal but trend of repeated sales should be tracked.

From a governance standpoint, the filer follows mandated disclosure, signalling procedural transparency. The signatory’s affirmation of no undisclosed adverse information mitigates immediate governance concerns. However, repeated sales within a short window might prompt questions on insider confidence, especially given the filer’s proximity to the board. While volumes are de-minimis, boards often monitor cumulative patterns to pre-empt perception risks. Continued adherence to Rule 10b5-1 or written trading plans would further shield the company from appearance-based scrutiny.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001855608
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BRIDGEBIO PHARMA, INC.
SEC File Number	001-38959
Address of Issuer	3160 Porter Drive Suite 250 Palo Alto CALIFORNIA 94304
Phone	(650) 391-9740
Name of Person for Whose Account the Securities are To Be Sold	HANNAH VALANTINE & DENIS VON KAEPPLER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	spouse of bod / bod is joint owner

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1542	67863.42	189880720	06/26/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/28/2021	Open Market Purchase	Open Market			1542	12/28/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
Hannah Valantine 3160 Porter Drive Suite 250 Palo Alto CA 94304	BBIO	06/10/2025	4292	171551.24
HANNAH A VALANTINE 3160 Porter Drive Suite 250 Palo Alto CA 94304	Common	06/10/2025	4292	171680.00

144: Remarks and Signature

Remarks
Date of Notice	06/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Valantine Hannah
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What amount of BridgeBio (BBIO) shares is proposed for sale in this Form 144?

1,542 common shares, valued at approximately $67,863.42.

Who is selling the BBIO shares disclosed in the Form 144?

The shares are to be sold by Hannah Valantine & Denis von Kaeppler, identified as the spouse and joint owner of a Board member.

When is the proposed BBIO share sale expected to occur?

The approximate sale date stated is 26 June 2025.

How many BBIO shares were sold by the insider in the past three months?

The filing lists 17,168 shares sold on 10 June 2025 across four transactions.

What percentage of BridgeBio’s outstanding shares does the proposed 1,542-share sale represent?

Roughly 0.0008 % of the company’s 189,880,720 outstanding shares.

On which exchange will the shares be sold?

The proposed transactions are to take place on the NASDAQ.